Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2023 (Event date: January 24, 2023; Filing date: January 25, 2023)
Headquarters: Melbourne, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
- Nasdaq Compliance: The Company received formal notification from The Nasdaq Stock Market LLC confirming it has regained compliance with the Minimum Bid Price Rule (Listing Rule 5550(a)(2)).
- Requirement Met: The Company's American Depositary Shares (ADS) maintained a minimum bid price of at least $1.00 per ADS.
- Status: The matter regarding the bid price deficiency is now closed.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operations, specific risks, contingencies, or unusual items beyond the resolution of the listing compliance issue.
Investor Verification Checklist
- Verify the current trading price of Alterity Therapeutics ADS to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the Company's development stage status and lack of commercial revenue in subsequent filings.
- Review the Company's cash position in the most recent Form 20-F to assess runway given the development stage classification.